Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept treat-and-extend for diabetic macular oedema
ACTRN12619000963123Phase 4Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- May 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Royal Adelaide Hospital. Primary endpoint: Mean change in best corrected visual acuity from baseline to month 12. Started May 2019; status: recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12619000963123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000963123.